Mechanisms of nephroprotective action of sodium-glucose cotransporter type 2 inhibitors.
ММ, R., ММ, B., NV, I., & MO, K. (2026). Mechanisms of nephroprotective action of sodium-glucose cotransporter type 2 inhibitors.. Wiadomosci lekarskie (Warsaw, Poland : 1960). https://doi.org/10.36740/WLek/220827
ММ R, ММ B, NV I, MO K. Mechanisms of nephroprotective action of sodium-glucose cotransporter type 2 inhibitors.. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2026; doi: 10.36740/WLek/220827
ММ R, ММ B, NV I, et al. Mechanisms of nephroprotective action of sodium-glucose cotransporter type 2 inhibitors.[J]. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2026. DOI: 10.36740/WLek/220827.
@article{2026,
author = {Rоsul ММ and Bletskan ММ and Ivano NV and Korabelschykova MO},
title = {Mechanisms of nephroprotective action of sodium-glucose cotransporter type 2 inhibitors.},
journal = {Wiadomosci lekarskie (Warsaw, Poland : 1960)},
year = {2026},
doi = {10.36740/WLek/220827},
note = {PMID: 42359875},
}
TY - JOUR AU - Rоsul ММ AU - Bletskan ММ AU - Ivano NV AU - Korabelschykova MO TI - Mechanisms of nephroprotective action of sodium-glucose cotransporter type 2 inhibitors. T2 - Wiadomosci lekarskie (Warsaw, Poland : 1960) PY - 2026 DO - 10.36740/WLek/220827 AN - PMID:42359875 ER -
OBJECTIVE: Aim: To study the potential mechanisms underlying the beneficial nephroprotective effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors. PATIENTS AND METHODS: Materials and Methods: An analysis of literature sources was conducted regarding the clinical, epidemiological, and fundamental aspects of the nephroprotective effects of SGLT-2 inhibitors. For this purpose, articles were searched for and selected in the PubMed database using the following keywords: "sodium-glucose cotransporter-2 inhibitors," "heart failure," "chronic kidney disease," and "cardiorenal syndrome," with a primary focus on studies published in the last 5 years. To provide context and explain the underlying mechanisms, several classical and fundamental studies relevant to the aim of the review were also included. CONCLUSION: Conclusions: SGLT-2 inhibitors exert nephroprotective effects through a complex of interrelated hemodynamic, metabolic, and cellular-molecular mechanisms that are largely independent of their hypoglycemic action. The combination of these mechanisms explains the clinically proven nephroprotective effect of SGLT-2 inhibitors in both patients with and without DM and justifies considering them not only as glucose-lowering agents but also as fundamental agents of pathogenetic therapy for chronic kidney disease.